Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, published by BEGELL HOUSE INC, serves as a vital platform for researchers and professionals engaged in the interdisciplinary fields of environmental health, pathology, and toxicology. With a history spanning from 1984 to the present, the journal is dedicated to disseminating high-quality research that explores the complexities of environmental threats to human health and their pathological implications. Its current ranking in the Q3 category across key areas including Health, Toxicology and Mutagenesis, Medicine (miscellaneous), and Pathology and Forensic Medicine underscores its relevance in the academic landscape. Despite not being an open-access journal, it remains an essential resource for those seeking to understand the impact of environmental factors on health outcomes. The journal's rigorous peer-review process and commitment to advancing knowledge make it an indispensable tool for students, researchers, and professionals striving to address pressing health and environmental challenges.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, published by Elsevier, is a renowned journal that explores critical advancements in the field of genetic toxicology and environmental mutagenesis. With an ISSN of 1383-5718 and an E-ISSN of 1879-3592, it ranks in Q3 for Genetics and Q2 for Health, Toxicology, and Mutagenesis as of 2023. This journal not only emphasizes the importance of environmental factors in genetic material alterations but also disseminates significant research findings that aid in understanding the implications for public health and safety. Operating from Amsterdam, Netherlands, it serves as a pivotal platform for researchers, professionals, and students, fostering an informed community keen on evolving the parameters of genetic research. Although it currently does not offer open access, the journal's commitment to high-quality peer-reviewed content ensures substantial contributions to the academic literature, enhancing our comprehension of mutagenic processes and their environmental triggers.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

GENOMICS is a prestigious journal published by Academic Press Inc Elsevier Science, dedicated to advancing the field of genetic research and molecular biology. With an impressive impact factor, this journal is recognized for its rigorous peer-review process and high-quality publications that cover a wide range of topics within the genomics discipline. Operating from the United States, GENOMICS has established itself as a vital resource for researchers, professionals, and students alike, standing at Q2 in the Genetics category according to the latest rankings. With a rich history dating back to 1987 and convergence extending to 2024, the journal highlights cutting-edge discoveries and methodologies, ensuring that its readership remains at the forefront of genetic advancements. Although currently not an open-access journal, articles published within its pages are often accessible through various academic platforms, enhancing worldwide reach and dissemination. For those engaged in the fields of biochemistry, genetics, and molecular biology, GENOMICS serves as an indispensable platform for impactful research and collaborative initiatives.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Reports of Biochemistry and Molecular Biology, published by VARASTEGAN INST MEDICAL SCIENCES, is a distinguished open access journal dedicated to advancing the fields of biochemistry and molecular biology. Since its inception in 2012, the journal has fostered a platform for researchers and professionals to disseminate their findings, contributing to a richer understanding of biochemical processes and molecular mechanisms. With a focus on innovative research and technology, the journal has established itself as a significant resource within its field, being classified in the Q3 category for Biochemistry and Molecular Biology by 2023. Notably, it has achieved respectable Scopus rankings, including a rank of #40/72 in Biochemistry (medical) as well as a common ground across multiple related categories. The journal’s commitment to open access ensures that its valuable content is freely available to the global scientific community, facilitating knowledge sharing among students, researchers, and professionals alike. Located in Mashhad, Iran, Reports of Biochemistry and Molecular Biology serves as a bridge between cutting-edge research and practical applications in the biochemistry and molecular biology domains.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.